Veliflapon (BioDeep_00000839644)
代谢物信息卡片
化学式: C23H23NO3 (361.16778480000005)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CCC(C1)C(C2=CC=C(C=C2)OCC3=NC4=CC=CC=C4C=C3)C(=O)O
InChI: InChI=1S/C23H23NO3/c25-23(26)22(17-6-1-2-7-17)18-10-13-20(14-11-18)27-15-19-12-9-16-5-3-4-8-21(16)24-19/h3-5,8-14,17,22H,1-2,6-7,15H2,(H,25,26)/t22-/m1/s1
描述信息
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D004791 - Enzyme Inhibitors > D016859 - Lipoxygenase Inhibitors
D002491 - Central Nervous System Agents > D000700 - Analgesics
C78274 - Agent Affecting Cardiovascular System
D000893 - Anti-Inflammatory Agents
D018501 - Antirheumatic Agents
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Zehra Tuğçe Gür, Burcu Çalışkan, Erden Banoglu. Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis.
European journal of medicinal chemistry.
2018 Jun; 153(?):34-48. doi:
10.1016/j.ejmech.2017.07.019. [PMID: 28784429] - Esther Titos, Joan Clària, Anna Planagumà, Marta López-Parra, Ana González-Périz, Joan Gaya, Rosa Miquel, Vicente Arroyo, Joan Rodés. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells.
Journal of leukocyte biology.
2005 Oct; 78(4):871-8. doi:
10.1189/jlb.1204747. [PMID: 16033810] - Serenella Rotondo, Katarzyna Krauze-Brzósko, Stefano Manarini, Virgilio Evangelista, Chiara Cerletti. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
European journal of pharmacology.
2004 Mar; 488(1-3):79-83. doi:
10.1016/j.ejphar.2004.02.006. [PMID: 15044038] - Jose M Valdivielso, Angel Montero, Kamal F Badr, Karen A Munger. Inhibition of 5-lipoxygenase activating protein decreases proteinuria in diabetic rats.
Journal of nephrology.
2003 Jan; 16(1):85-94. doi:
NULL. [PMID: 12649539] - José M Valdivielso, Angel Montero, Karen A Munger, Kamal F Badr. Inhibition of 5-LO activating protein (FLAP) activity decreases proteinuria in streptozotocin (STZ)-induced diabetic rats.
Advances in experimental medicine and biology.
2002; 507(?):79-83. doi:
10.1007/978-1-4615-0193-0_13. [PMID: 12664568] - G Bannenberg, S E Dahlén, M Luijerink, G Lundqvist, R Morgenstern. Leukotriene C4 is a tight-binding inhibitor of microsomal glutathione transferase-1. Effects of leukotriene pathway modifiers.
The Journal of biological chemistry.
1999 Jan; 274(4):1994-9. doi:
10.1074/jbc.274.4.1994. [PMID: 9890956] - F M Cunningham, M Andrews, M F Landoni, P Lees. Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.
Journal of veterinary pharmacology and therapeutics.
1997 Aug; 20(4):296-307. doi:
10.1046/j.1365-2885.1997.00064.x. [PMID: 9280370] - B Dahlén, M Kumlin, E Ihre, O Zetterström, S E Dahlén. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005.
Thorax.
1997 Apr; 52(4):342-7. doi:
10.1136/thx.52.4.342. [PMID: 9196517] - H Groen, H L Moesker, O R Leeuwenkamp, F A Sollie, J H Jonkman. No pharmacokinetic or pharmacodynamic interaction between theophylline and the leukotriene biosynthesis inhibitor BAY x 1005.
Journal of clinical pharmacology.
1996 Jul; 36(7):639-46. doi:
10.1002/j.1552-4604.1996.tb04229.x. [PMID: 8844447] - G Rossoni, A Sala, F Berti, T Testa, C Buccellati, C Molta, R Muller-Peddinghaus, J Maclouf, G C Folco. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes.
The Journal of pharmacology and experimental therapeutics.
1996 Jan; 276(1):335-41. doi:
10.1163/2211730x96x00180. [PMID: 8558451] - A Hatzelmann, J Goossens, R Fruchtmann, K H Mohrs, S Raddatz, R Müller-Peddinghaus. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein.
Biochemical pharmacology.
1994 Jun; 47(12):2259-68. doi:
10.1016/0006-2952(94)90264-x. [PMID: 8031320] - R Müller-Peddinghaus, R Fruchtmann, H J Ahr, B Beckermann, K Bühner, B Fugmann, B Junge, M Matzke, C Kohlsdorfer, S Raddatz. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics.
Journal of lipid mediators.
1993 Mar; 6(1-3):245-8. doi:
". [PMID: 8395246]